Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).

Michael B AtkinsOpeyemi A JegedeNaomi B HaasDavid F McdermottMehmet Asim BilenMark SteinJeffrey SosmanRobert AlterElizabeth R PlimackMoshe C OrnsteinMichael HurwitzDavid J PeaceDavid J EinsteinPaul J CatalanoHans HammersMeredith M Regan

Published in: Journal for immunotherapy of cancer (2024)

Nivolumab monotherapy with salvage nivolumab/ipilimumab in non-responders is an active treatment approach in treatment-naïve patients with aRCC and, similar to nivolumab/ipilimumab in CheckMate 214, results in substantial TFS and toxicity-free TFS. TFS was greatest in patients with favorable-risk disease, supporting the use of an immunotherapy-only regimen in this population.

Keyphrases

phase ii study
free survival
oxidative stress
replacement therapy
locally advanced
rectal cancer